Luspatercept (ACE-536), an ActRIIB, with the modified extracellular domain of ActRIIB fused to the Fc fragment, after a promising phase 2 trial [121], was administered to myelodysplastic syndromes in a large phase 3 trial [122]. Here, ACVR2B is linked to myelodysplastic syndrome.